Journal
FRONTIERS IN PHYSIOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fphys.2021.709703
Keywords
inflammasome; heart failure; inflammation; cardiomyocyte; fibroblast; macrophage
Categories
Funding
- UMHS-PUHSC Joint Institute for Translational and Clinical Research [BMU2019JI007]
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China [82030072, 81822003, 81830009]
- Beijing Municipal Natural Science Foundation [7191013]
- Key Clinical Projects of Peking University Third Hospital [BYSYZD2019022]
Ask authors/readers for more resources
Inflammation promotes the development of heart failure by activating the inflammasome, which triggers the cleavage and activation of proinflammatory cytokines. Inhibition of the inflammasome has shown to reduce hospitalizations and mortality in HF patients. Activation of the inflammasome under various pathologic conditions contributes to cardiac hypertrophy, fibrosis, and pyroptosis in the progression of HF.
Inflammation promotes the development of heart failure (HF). The inflammasome is a multimeric protein complex that plays an essential role in the innate immune response by triggering the cleavage and activation of the proinflammatory cytokines interleukins (IL)-1 beta and IL-18. Blocking IL-1 beta with the monoclonal antibody canakinumab reduced hospitalizations and mortality in HF patients, suggesting that the inflammasome is involved in HF pathogenesis. The inflammasome is activated under various pathologic conditions that contribute to the progression of HF, including pressure overload, acute or chronic overactivation of the sympathetic system, myocardial infarction, and diabetic cardiomyopathy. Inflammasome activation is responsible for cardiac hypertrophy, fibrosis, and pyroptosis. Besides inflammatory cells, the inflammasome in other cardiac cells initiates local inflammation through intercellular communication. Some inflammasome inhibitors are currently being investigated in clinical trials in patients with HF. The current evidence suggests that the inflammasome is a critical mediator of cardiac inflammation during HF and a promising therapeutic target. The present review summarizes the recent advances in both basic and clinical research on the role of the inflammasome in HF.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available